Nektar Therapeutics <NKTR.OQ> expected to post a loss of 17 cents a share - Earnings Preview
Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports results on March 6 (estimated) for the period ending December 31 2024
The San Francisco California-based company is expected to report a 25.0% increase in revenue to $29.86 million from $23.89 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nektar Therapeutics is $4.00, above its last closing price of $0.80.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.22 | -0.21 | -0.18 | Beat | 14.6 |
Jun. 30 2024 | -0.21 | -0.20 | -0.25 | Missed | -22.8 |
Mar. 31 2024 | -0.19 | -0.19 | -0.19 | Met | 0 |
Dec. 31 2023 | -0.22 | -0.21 | -0.22 | Missed | -3.6 |
Sep. 30 2023 | -0.21 | -0.20 | -0.24 | Missed | -20.3 |
Jun. 30 2023 | -0.31 | -0.28 | -0.27 | Beat | 4.9 |
Mar. 31 2023 | -0.23 | -0.25 | -0.32 | Missed | -26.7 |
Dec. 31 2022 | -0.44 | -0.45 | -0.32 | Beat | 29.3 |
This summary was machine generated March 4 at 11:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Alphabet Dodges a Bullet on Antitrust, but It's Still Not Out of the Woods
Key PointsAlphabet is involved in two antitrust cases, one involving search and another related to its ad tech businesses.The judge in the first case has already suggested remedies, but the consequences for the second case have yet to be determined.Investors have been buying up Alphabet's stock now
Oracle Q1 FY2026 Earnings: Cloud Surge and Record RPO Fuel AI Optimism
TradingKey - Oracle Corporation (NYSE: ORCL) posted mixed Q1 FY2026 results, with total revenue and adjusted EPS slightly below consensus amid a shift to cloud services, but cloud revenue beat expectations with robust 28% growth. A massive RPO backlog of $455 billion, up 359% YoY
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks ahead
Eurozone June Harmonised Inflation Commentary: Short-Term Profit Potential for Euro Bulls
TradingKey - On 17 July 2025, the Eurozone's June Harmonised Inflation data was released, aligning with market expectations. The headline HICP rose slightly from 1.9% in May to 2.0%, while core HICP remained steady at 2.3%.
